Canaccord Genuity Group began coverage on shares of GreenLight Biosciences (NASDAQ:GRNA – Get Rating) in a research report sent to investors on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $4.00 target price on the stock.
Separately, Credit Suisse Group began coverage on GreenLight Biosciences in a research report on Friday, October 14th. They set an outperform rating and a $5.50 price target on the stock.
Get GreenLight Biosciences alerts:GreenLight Biosciences Trading Up 3.6 %
Shares of GreenLight Biosciences stock opened at $1.14 on Thursday. The business's fifty day moving average price is $1.76 and its two-hundred day moving average price is $2.75. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.20. GreenLight Biosciences has a 1-year low of $1.05 and a 1-year high of $15.80.
Hedge Funds Weigh In On GreenLight Biosciences
A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in shares of GreenLight Biosciences by 340.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 213,329 shares of the company's stock worth $495,000 after acquiring an additional 164,893 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of GreenLight Biosciences by 47.2% in the 3rd quarter. California State Teachers Retirement System now owns 71,001 shares of the company's stock worth $165,000 after acquiring an additional 22,773 shares during the last quarter. Baird Financial Group Inc. acquired a new position in shares of GreenLight Biosciences in the 3rd quarter worth $6,628,000. State Street Corp grew its holdings in shares of GreenLight Biosciences by 108.2% in the 3rd quarter. State Street Corp now owns 811,721 shares of the company's stock worth $1,883,000 after acquiring an additional 421,797 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of GreenLight Biosciences by 29.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,205,436 shares of the company's stock worth $2,797,000 after acquiring an additional 274,020 shares during the last quarter. 23.94% of the stock is currently owned by institutional investors and hedge funds.GreenLight Biosciences Company Profile
(Get Rating)
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Featured Stories
- Get a free copy of the StockNews.com research report on GreenLight Biosciences (GRNA)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.